Compare EVAX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | CCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 27.8M |
| IPO Year | 2020 | 2022 |
| Metric | EVAX | CCEL |
|---|---|---|
| Price | $3.97 | $3.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 33.7K | 7.8K |
| Earning Date | 05-07-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | ★ N/A | $368.00 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $1.62 | $2.72 |
| 52 Week High | $12.15 | $5.52 |
| Indicator | EVAX | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 52.34 |
| Support Level | $2.76 | $3.18 |
| Resistance Level | $4.65 | $4.08 |
| Average True Range (ATR) | 0.29 | 0.24 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 4.22 | 30.43 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.